Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

Australia

Austria

Belgium

Brazil *

Canada

China *

Denmark

Finland

France

Germany

Hong Kong (China) *

India *

Ireland

Italy

Japan *

Luxembourg

Mexico *

Netherlands

Norway

Philippines *

Republic of Korea *

Singapore *

Spain

Sweden

Switzerland

Thailand *

United Kingdom

United States

img-spleen-targeted-neoantigen-dna-vaccine-personalized-immunotherapy-hepatocellular-carcinoma-1920x640

Literature - Publication Review

Spleen-targeted neoantigen DNA vaccine for personalized immunotherapy of hepatocellular carcinoma

Researchers investigated how a spleen-targeted DNA vaccine, delivered via RBC-hitchhiked nanoparticles, effectively induced robust neoantigen specific T cell responses in hepatocellular carcinoma (HCC). This approach not only inhibited tumor growth, but also showed potential for complete tumor regression when combined with anti-PD-1 therapy, offering a promising strategy for personalized immunotherapy in HCC.

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

営業担当者から連絡を受けることに同意します。

お名前（名）

お名前（姓）

国

メールアドレス

会社名

郵便番号

勤務先電話番号

職種

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Download Resource

Spleen-targeted neoantigen DNA vaccine for personalized immunotherapy of hepatocellular carcinoma

Download Literature - Publication Review